Pusan National University Yangsan Hospital
pnuyh.or.krLive pipeline data from ClinicalTrials.gov, refreshed daily.
Total trials
104
Active
31
Phase 3
1
Total enrollment
14,118
Pipeline matrix
Showing 9 of 9 active programs · click any cell for trials
| Intervention | Early Phase 1 | Phase 1 | Phase 2 | Phase 3 | Phase 4 | N/A | Total |
|---|---|---|---|---|---|---|---|
| Indocyanine green (ICG) injection for intraoperative lymph node imaging | — | — | — | — | — | 1 | |
| Sevoflurane | — | — | — | — | 4 | ||
| Remimazolam | — | — | — | — | — | 4 | |
| propofol | — | — | — | — | 2 | ||
| Flumazenil | — | — | — | — | — | 1 | |
| normal saline | — | — | — | — | — | 1 | |
| Mirogabalin | — | — | — | — | — | 1 | |
| Duloxetine | — | — | — | — | — | 1 | |
| Desflurane | — | — | — | — | — | 1 |
Next readouts
- 2025-05-31
- 2025-12-31
- 2026-02
- 2026-12-31
- 2027-04-01
- 2028-12-31
Top conditions
- Stroke7
- Spinal Cord Injuries5
- Remimazolam4
- Sarcopenia4
- Muscular Sarcoidosis3
- Coronary Artery Disease3
- EEG2
- FNIRS2
Frequently asked questions about Pusan National University Yangsan Hospital
- How many clinical trials does Pusan National University Yangsan Hospital have on ClinicalTrials.gov?
- Pusan National University Yangsan Hospital is listed as the lead sponsor on 104 clinical trials in ClinicalTrials.gov, 31 of which are currently active (recruiting, enrolling, or ongoing).
- How many of Pusan National University Yangsan Hospital's trials are in Phase 3?
- 1 of Pusan National University Yangsan Hospital's trials are in Phase 3, spread across 9 active drug programs.
- What therapeutic areas does Pusan National University Yangsan Hospital focus on?
- Pusan National University Yangsan Hospital's most-studied conditions on ClinicalTrials.gov are Stroke, Spinal Cord Injuries, Remimazolam, Sarcopenia, Muscular Sarcoidosis.
- When are Pusan National University Yangsan Hospital's next clinical trial readouts?
- Pusan National University Yangsan Hospital has 6 upcoming primary-completion readouts tracked here; the soonest is “Comparison of the Efficacy and Safety of Mirogabalin and Duloxetine in Chemotherapy-induced Peripheral Neuropathy in a Randomized Controlled Trial: a Quality of Life Study in Cancer Survivors”, expected around 2025-05-31.